Immunogenicity of a recombinant lumpy skin disease virus (neethling vaccine strain) expressing the rabies virus glycoprotein in cattle

By Aspden K.   Dijk A.A.v.   Bingham J.   Cox D.   Passmore J.-A.   Williamson A.-L.  

Vaccine, Vol. 20, Iss. 21, 2002-06 ,pp. : 2693-2701

Elsevier

Access to resources Recommend Favorite

Human adenovirus type 5 vectors expressing rabies glycoprotein

By Yarosh O.K.   Wandeler A.I.   Graham F.L.   Campbell J.B.   Prevec L.  

Vaccine, Vol. 14, Iss. 13, 1996-09 ,pp. : 1257-1264

Elsevier

Access to resources Recommend Favorite

Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy

By Strady C.   Jaussaud R.   Beguinot I.   Lienard M.   Strady A.  

Vaccine, Vol. 18, Iss. 24, 2000-06 ,pp. : 2661-2667

Elsevier

Access to resources Recommend Favorite

Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis

By Hanlon C.A.   DeMattos C.A.   DeMattos C.C.   Niezgoda M.   Hooper D.C.   Koprowski H.   Notkins A.   Rupprecht C.E.  

Vaccine, Vol. 19, Iss. 28, 2001-07 ,pp. : 3834-3842

Elsevier

Access to resources Recommend Favorite

Raccoon poxvirus live recombinant feline panleukopenia virus VP2 and rabies virus glycoprotein bivalent vaccine

By Liangbiao H.   Ngichabe C.   Trimarchi C.V.   Esposito J.J.   Scott F.W.  

Vaccine, Vol. 15, Iss. 12, 1997-08 ,pp. : 1466-1472

Elsevier

Access to resources Recommend Favorite